advertisement
Journal of Ocular Pharmacology and Therapeutics 21
Showing records 1 to 21 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Bastia E
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Fuwa M
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94894 Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
Fridman G; Sadlak N
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 338-342
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Shimazaki A
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Toris C
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
94894 Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
Sadlak N
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 338-342
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Bukowski JM
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94894 Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
Eliassi-Rad B
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 338-342
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Kirihara T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94894 Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
Desai MA
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 338-342
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Brambilla S
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Taniguchi T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Galli C
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Iwamura R; Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Almirante N; Bergamini MVW
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Yoneda K; Kato M
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Lucarini L; Navratil T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Morishima K
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
95282 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
Impagnatiello F
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 215-222
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Shams NK
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
